The Management Team

Cathrin Schleussner, PhD

Chief Executive Officer

Dr Schleussner is the CEO of T-Balance Therapeutics GmbH. She holds a doctorate in Biology. She has extensive experience in the fields of immunology and molecular oncology. In the pharmaceutical industry she was responsible for licensing and cooperations as well as for corporate development. Besides her many years on the Board of Directors of a publicly listed company, she is active as business angel investor in the fields of medical technology and biotechnology.

Markus A. Lang, PhD

Development Strategy & Operations Advisor

Dr Lang has over 15 years’ experience in successfully developing, manufacturing and approving biopharmaceutical medicinal products and has relevant expertise in the highly competitive and heavily regulated field of biopharmaceuticals. He made important key contributions to development of several marketed drugs [Minjuvi®, Cytelzo®, Removab®, Pradaxa®). The doctor of chemistry provides consultancy to various customers who benefit in particular from his extensive experience in international project management and successful P&L management of development portfolios in medium-sized companies and corporate environments.

Stephan Wehselau

Financial Advisor / Member of the Board

Mr Wehselau is a serial entrepreneur with more than 20 years of C-level experience as CFO, COO and CEO and a success record of raising venture and private capital of over 400 million dollars. He is President & COO of Spexis AG (SPEX). The qualified economist was previously involved in founding five life sciences companies, among others. Before Stephan Wehselau moved into the start-up and VC / PE industry, he began his career in the pharma industry at Boehringer Mannheim and Roche.

Geoff Down, MD

Medical and Clinical Development Advisor

Dr Down practised hospital medicine for 10 years in London, UK. He has subsequently spent almost 30 years in industry, working in a range of companies from start-up to major pharmaceuticals. His principal experience is in early clinical development but has also covered the full range of development from translational investigation to registration and post-licence activities. He has participated in corporate due diligence, investment and divestment.

Dr. Brenda Rascon

Chief Operations Officer and Regulatory Affairs Head
Dr. Rascon is currently the Chief Operating Officer and Head of Regulatory Affairs at T-Balance Therapeutics and leads daily operations, which encompass Regulatory Affairs, CMC, Clinical Operations, and Quality Systems. Prior to joining T-Balance Therapeutics, Brenda held several positions in Regulatory Affairs for biopharmaceuticals in a large, top 20 global pharmaceutical company and in small biopharmaceutical companies. Dr. Rascon was previously a member of the senior management team at a biotech company, where she oversaw the successful regulatory process of an oncology biosimilar currently on the European market. In addition, she has played a vital role in due diligence activities for product licensing and M&A purposes. Dr. Rascon holds a PhD in biology and was active in academic research in the US and EU prior to entering the biopharmaceutical industry.

Dr. Annette Galler

Chief Development Officer

Dr. Galler is Chief Development Officer at T-Balance Therapeutics and is responsible for the evaluation and selection of indications as well as the strategic development plans for Tregalizumab and other projects.

Annette has more than 15 years of experience in the pharmaceutical industry, covering almost the entire value chain from research, drug development and licensing to product launch and commercialisation. Prior to T-Balance Therapeutics, Annette was a member of the senior management of a contract research organisation. Prior to that, she successfully led global development programmes in oncology and immunology in one of the top 20 global pharmaceutical companies. In this role, she led several due diligence projects and was an integral member of licensing and negotiation teams. In addition, Annette has profound marketing knowledge and was responsible for the launch and re-launch of biologics.

Annette holds a PhD in biochemistry and is co-inventor on patents for the treatment of inflammatory diseases.

Sonja Ludscheidt

Project Coordinator

After her studies in bioinformatics, Ms Ludscheidt broadened her experience in large IT projects and budgeting in the Financial Services sector of various global banks before taking up her position as Project Coordinator at T-Balance Therapeutics GmbH. Today, Sonja is the contact person for all internal and external partners concerning coordination, controlling, accounting, contract management, and the IT infrastructure.

Dr. Manfred Papaspyrou

Business & Technical Consultant for Biopharmaceuticals

Dr Papaspyrou can already look back on a long and successful career in engineering services for biopharmaceutical production. He advises T-Balance Therapeutics GmbH on identifying potential partners for cell line development, analytical methods, process development, and GMP in the production of drug substances and medicinal products.

Prof. Gregor Schulz

Clinical Development Advisor

Professor Schulz has many years of management experience in plasma protein products and biotechnology. He is a medical specialist in pediatrics and transfusion medicine, and has worked as a medical practitioner and scientific researcher in clinical immunology, haematology and transfusion medicine for many years. Professor Schulz advises T-Balance Therapeutics GmbH on clinical development.